Traversa, Donato
Raue, Katharina
Ringeisen, Hannah
Blazejak, Katrin
Bisterfeld, Katrin
Di Cesare, Angela
Colombo, Mariasole
Böhm, Claudia
Strube, Christina
Pollmeier, Matthias
Funding for this research was provided by:
Bayer
Article History
Received: 22 December 2021
Accepted: 28 January 2022
First Online: 22 February 2022
Declarations
:
: All the procedures that involved animals complied with the Directive 2010/63/EU of the European Parliament and of the council of 22nd September 2010 on the protection of the animals used for scientific purposes, the German animal protection act and the German welfare regulations for laboratory animals. Animal experiments to evaluate the drug combination in cats were approved by the ethics commission of the Animal Care and Use Committee of the German Lower Saxony State Office for Consumer Protection and Food Safety (Niedersaechisches Landesamt fuer Verbraucherschutz und Lebensmittelsicherheit—LAVES) under reference number 33.9-42502-04-19/3235 (Study 1) as well as by the Nature, Environment and Consumer Protection in North Rhine Westphalia (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen—LANUV) under reference number N0200a0220 (Study 2, approval for Bayer Animal Health GmbH). Snail breeding and infection was approved by the Italian Ministry of Health (DGSAF 0019336-P 15/07/2019, DGSAF 00004761-A 26/02/2020, DGSAF n. 0014846-A 02/07/2020) and by the Interinstitutional Ethical Committee for Animal Experimentation (CEISA—Prot. N. 03/2019).
: Not applicable.
: This study was funded by Bayer Animal Health GmbH, now an Elanco Animal Health company. CB, HR and MP are employees of Bayer Animal Health, and KBl was an employee during the time the study was conducted. DT, ADC and MC declare that the snail infection and breeding did not coincide or overlap with other similar laboratory procedures on <i>Troglostrongylus brevior</i>.